e-learning
resources
Virtual 2020
Pre-Congress Content
Molecular alterations and immunology in lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells
S. Yang (Iksan, Republic of Korea), M. Kim (Iksan, Republic of Korea), S. Kim (Iksan, Republic of Korea), M. Kim (Iksan, Republic of Korea)
Source:
Virtual Congress 2020 – Molecular alterations and immunology in lung cancer
Session:
Molecular alterations and immunology in lung cancer
Session type:
E-poster session
Number:
1648
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Yang (Iksan, Republic of Korea), M. Kim (Iksan, Republic of Korea), S. Kim (Iksan, Republic of Korea), M. Kim (Iksan, Republic of Korea). Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells. 1648
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Definition and history of sarcoidosis
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Related content which might interest you:
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up
Source: Eur Respir J 2009; 33: 436-440
Year: 2009
Epidermal growth factor receptor (EGFR) gene mutation testing prior to tyrosine kinase inhibitors (TKI) treatment – prospective data from the Czech TULUNG registry
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020
Targeted therapy in nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 284–298
Year: 2009
Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease
Source: Eur Respir Rev, 26 (146) 170061; 10.1183/16000617.0061-2017
Year: 2017
Safety and efficacy of an inhaled epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (BIBW 2948) in COPD
Source: Annual Congress 2009 - New drugs for airways disease
Year: 2009
Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC
Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers
Year: 2020
Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
Source: Eur Respir J 2012; 39: 366-372
Year: 2012
Blocking beta adrenergic signaling may be a target for overcoming EGFR TKI resistance.
Source: International Congress 2018 – Lung cancer: from the bench to the bedside
Year: 2018
Detection of epidermal growth factor receptor mutation in plasma as predictor of gefitinib response in non small cell lung cancer
Source: Annual Congress 2008 - Therapy in thoracic oncology
Year: 2008
EGFR tyrosine kinase inhibitors
versus
chemotherapy in
EGFR
wild-type pre-treated advanced nonsmall cell lung cancer in daily practice
Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017
Year: 2017
Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis
Source: Eur Respir J 2013; 41: 417-424
Year: 2013
Bradykinin phosphorylates ERK1/2 through epidermal growth factor receptor transactivation in human lung fibroblasts
Source: Eur Respir J 2005; 26: Suppl. 49, 341s
Year: 2005
Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Effect of PDGF receptor tyrosine kinase inhibitor AG1296 on bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2004 - Pulmonary fibrosis - new insights
Year: 2004
SiRNA mediated growth factor receptors inhibition in A549 cell model of lung cancer gene therapy: insulin-like growth factor-I receptor (IGF-R1) blockade produces changes that potentially induce anti-tumor immunity
Source: Annual Congress 2008 - Biology in thoracic tumours
Year: 2008
Clinical profile of newly diagnosed patients of non small cell carcinima with epidermal growth factor receptor positivity on oral tyrosine kinase inhibitor therapy
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors
Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer
Year: 2021
Lung adenocarcinoma patients of young age have lower
EGFR
mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
Source: ERJ Open Res, 3 (3) 00092-2016; 10.1183/23120541.00092-2016
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept